Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
Grifols has announced intriguing results in a subgroup of patients in a large Alzheimer's disease study, Ambar, but the finding could also benefit other suppliers of…
A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.
Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.